• Publications
  • Influence
Oral rivaroxaban for symptomatic venous thromboembolism.
TLDR
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. Expand
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
TLDR
Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty. Expand
Fibrinolysis for patients with intermediate-risk pulmonary embolism.
TLDR
In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. Expand
Haemostatic changes in pregnancy.
TLDR
There is a 4- to 10-fold increased thrombotic risk throughout gestation and the postpartum period and disruption of anticoagulant mechanisms, for example, autoantibodies to annexin V may increase pregnancy complications in patients with antiphospholipid antibodies (APLA). Expand
Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
TLDR
Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. Expand
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
TLDR
The use of LMWH for VTE prevention in cancer patients undergoing laparoscopic surgery may be recommended as for laparotomy and mechanical methods are not recommended as monotherapy except when pharmacological methods are contraindicated. Expand
Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial
TLDR
PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting and more widespread availability of PCC is warranted to ensure its benefits in appropriate patients. Expand
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
TLDR
Enoxaparin is safe and effective in prevention of pregnancy loss in women with inherited and acquired thrombophilia and in Women with antiphospholipid syndrome. Expand
A single genetic origin for a common Caucasian risk factor for venous thrombosis.
TLDR
Haplotype analyses using six dimorphic sites in the factor V gene for 117 Caucasian subjects of Jewish, Arab, Austrian, and French origin who were homozygous for nt A1691 compared with 167 controls support a single origin for this polymorphism. Expand
Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.
TLDR
Thrombophilic polymorphisms are common in women with fetal loss without apparent cause and are associated with late pregnancy wastage and Combinations of TP increase the risk for fetal loss. Expand
...
1
2
3
4
5
...